{
    "id": 32137,
    "fullName": "YES1 T348I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "YES1 T348I is a gatekeeper mutation that lies within the protein kinase domain of the Yes1 protein (UniProt.org). T348I has been demonstrated to confer Yes1 inhibitor resistance in combination with Yes1 amplification in culture (PMID: 31391186), but has not been biochemically characterized and therefore, its effect on Yes1 protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7525,
        "geneSymbol": "YES1",
        "terms": [
            "YES1",
            "c-yes",
            "HsT441",
            "P61-YES",
            "Yes"
        ]
    },
    "variant": "T348I",
    "createDate": "01/20/2020",
    "updateDate": "01/20/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an esophageal cancer cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to CH6953755 treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastroesophageal junction adenocarcinoma cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to Sprycel (dasatinib) treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastroesophageal junction adenocarcinoma cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to CH6953755 treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 9238,
                "therapyName": "CH6953755",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an esophageal cancer cell line harboring YES1 amplification and expressing YES1 T348I demonstrated resistance to Sprycel (dasatinib) treatment in culture (PMID: 31391186).",
            "molecularProfile": {
                "id": 34630,
                "profileName": "YES1 T348I YES1 amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16801,
                    "pubMedId": 31391186,
                    "title": "YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31391186"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34629,
            "profileName": "YES1 T348I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34630,
            "profileName": "YES1 T348I YES1 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}